Analysts Are Bullish on These Healthcare Stocks: RARX, TXMD

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ra Pharmaceuticals (NASDAQ: RARX), TherapeuticsMD (NYSE MKT: TXMD) and OncoMed Pharma (NASDAQ: OMED) with bullish sentiments.

Ra Pharmaceuticals (NASDAQ: RARX)

In a report released today, Eun Yang from Jefferies reiterated a Buy rating on Ra Pharmaceuticals (NASDAQ: RARX), with a price target of $25. The company’s shares opened today at $12.75, close to its 52-week low of $12.33.

Yang said:

“Roughly in-line 3Q16 net loss of $8.1M; our estimated cash of $116M at end- FY16 should be at least sufficient into 2H18 based on our forecast. Key catalyst is Ph2 data for lead product RA101495 in PNH pts in 2H17; if positive (similar to Soliris), we view >100% potential upside as likely from current levels.”

According to TipRanks.com, Yang is a 3-star analyst with an average return of 1.8% and a 49.8% success rate. Yang covers the Healthcare sector, focusing on stocks such as DBV Technologies S.A. – American, Achillion Pharmaceuticals, and Ionis Pharmaceuticals Inc.

Currently, the analyst consensus on Ra Pharmaceuticals is Strong Buy and the average price target is $23.33, representing an 83.0% upside.

In a report issued on November 21, BMO Capital also reiterated a Buy rating on the stock with a $26 price target.TherapeuticsMD (NYSE MKT: TXMD)

In a report released yesterday, Matthew Andrews from Jefferies reiterated a Buy rating on TherapeuticsMD (NYSE MKT: TXMD), with a price target of $18. The company’s shares opened today at $5.88.

According to TipRanks.com, Andrews is a 1-star analyst with an average return of -3.6% and a 29.4% success rate. Andrews covers the Healthcare sector, focusing on stocks such as Anthera Pharmaceuticals, Infinity Pharma, and Ascendis Pharma.

Currently, the analyst consensus on TherapeuticsMD is Strong Buy and the average price target is $12, representing a 104.1% upside.

In a report issued on November 21, Oppenheimer also initiated coverage with a Buy rating on the stock with a $12 price target.OncoMed Pharma (NASDAQ: OMED)

In a report released yesterday, Brian Abrahams from Jefferies reiterated a Buy rating on OncoMed Pharma (NASDAQ: OMED), with a price target of $15. The company’s shares opened today at $8.88, close to its 52-week low of $8.07.

According to TipRanks.com, Abrahams is a 3-star analyst with an average return of 1.7% and a 48.7% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as DBV Technologies S.A. – American, Achillion Pharmaceuticals, and Protalix Biotherapeutics.

OncoMed Pharma has an analyst consensus of Strong Buy, with a price target consensus of $14.50.